Biologics and postbiologics: novel immunotherapeutics for the induction and maintenance of remission

Drug Discovery Today

Volumn 15, Issue 1-2, 2010, Pages 71-77

  van Eden, Willem ^a   Lisse, Jeffrey ^b   Prakken, Berent ^c,d   Albani, Salvatore ^b,d  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d EUREKA Institute for Translational Medicine   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 2; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DNAJP1; ETANERCEPT; GLYCOPROTEIN GP 39; HEAT SHOCK PROTEIN 60; IMMUNOMODULATING AGENT; METHOTREXATE; PLACEBO; PREDNISONE; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; AUTOIMMUNE DISEASE; CLINICAL STUDY; CLINICAL TRIAL; DRUG RESEARCH; DRUG RESPONSE; DRUG TOLERANCE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOTHERAPY; NONHUMAN; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; TOXICITY TESTING; VACCINATION;

ANIMALS; AUTOIMMUNE DISEASES; BIOLOGICAL PRODUCTS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; EPITOPES; HUMANS; IMMUNOLOGIC FACTORS; MODELS, IMMUNOLOGICAL; REMISSION INDUCTION; T-LYMPHOCYTES; TRANSLATIONAL RESEARCH;

EID: 74149090107     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2008.12.010     Document Type: Review

References (63)

1. Firestein G.S. The T cell cometh: interplay between adaptive immunity and cytokine networks in rheumatoid arthritis. J. Clin. Invest. 114 (2004) 471-474
2. Singh R., et al. Emerging biologic therapies in rheumatoid arthritis: cell targets and cytokines. Curr. Opin. Rheumatol. 17 (2005) 274-279
3. Pollard L., and Choy E. Rheumatoid arthritis: non-tumor necrosis factor targets. Curr. Opin. Rheumatol. 17 (2005) 242-246
4. Ehrenstein M.R., et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J. Exp. Med. 200 (2005) 277-285
5. Valencia X., et al. TNF downmodulates the function of human CD4 + CD25hi T-regulatory cells. Blood 108 (2006) 253-261
6. Firestein G.S., and Zvaifler N.J. How important are T cells in chronic rheumatoid synovitis? II. T cell-independent mechanisms from beginning to end. Arthritis Rheum. 46 (2002) 298-308
7. Raza K., et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res. Ther. 7 (2005) R784-R795
8. Hata H., et al. Distinct contribution of IL-6, TNF-{alpha}, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J. Clin. Invest. 114 (2004) 582-588
9. Choy E.H.S., and Panayi G.S. Cytokine Pathways and Joint Inflammation in Rheumatoid Arthritis. N. Engl. J. Med. 344 (2001) 907-916
10. Roord S., et al. Modulation of T cell function by combination of epitope specific and low dose anticytokine therapy controls autoimmune arthritis. PLoS ONE 1 (2006) e87
11. Albani S., and Prakken B. T cell epitope-specific immune therapy for rheumatic diseases [review]. Arthritis Rheum. 54 (2006) 19-25
12. Lugering A., et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 121 (2001) 1145-1157
13. Nadkarni S., et al. anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J. Exp. Med. 204 (2007) 33-39 Epub 2007 January 2. Erratum in: J. Exp. Med. 2007 204, 205
14. Sieper J., and Van Den Brande J. Diverse effects of infliximab and etanercept on T lymphocytes [review]. Semin. Arthritis Rheum. 34 5 Suppl. 1 (2005) 23-27
15. Becher B., et al. Inhibition of Th1 polarization by soluble TNF receptor is dependent on antigen-presenting cell-derived IL-12. J. Immunol. 162 (1999) 684-688
16. Genovese M., et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 46 (2002) 1443-1450
17. St Clair E., et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 50 (2004) 3432-3443
18. Quinn M., et al. Very early treatment with infliximab in addition to methotrexate in early, poor prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double blind, placebo-controlled trial. Arthritis Rheum. 52 (2005) 27-35
19. Genovese M.C., et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med. 353 (2005) 1114-1123
20. Tsokos G.C. B cells, be gone - B-cell depletion in the treatment of rheumatoid arthritis. N. Engl. J. Med. 350 (2004) 2546-2548
21. Asquith D.L., and McInnes I.B. Emerging cytokine targets in rheumatoid arthritis. Curr. Opin. Rheumatol. 19 (2007) 246-251
22. Allaart C.F., et al. Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study. Clin. Exp. Rheumatol. 24 6 Suppl. 43 (2006) S077-82
23. St Clair E.W., et al. New reagents on the horizon for immune tolerance. Ann. Rev. Med. 58 (2007) 329-346
24. Goekoop-Ruiterman Y.P.M., et al. Comparison of treatment strategies in early rheumatoid arthritis a randomized trial. Ann. Intern. Med. 146 (2007) 406-415
25. Breedveld F., et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54 (2005) 26-37
26. Manadan A.M., and Block J.A. Rheumatoid arthritis: beyond tumor necrosis factor-alpha antagonists, B cell depletion, and T cell blockade. Am. J. Ther. 15 (2008) 53-58
27. Honda A., et al. Vaccination with an immunodominant peptide of bovine type II collagen induces an anti-TCR response, and modulates the onset and severity of collagen-induced arthritis. Int. Immunol. 16 (2004) 737-745
28. Mimran A., et al. DNA vaccination with CD25 protects rats from adjuvant arthritis and induces an antiergotypic response. J. Clin. Invest. 113 (2004) 924-932
29. Cohen I.R., et al. Tregs in T cell vaccination: exploring the regulation of regulation. J. Clin. Invest. 114 (2004) 1227-1232
30. Panoutsakopoulou V., et al. Suppression of autoimmune disease after vaccination with autoreactive T cells that express Qa-1 peptide complexes. J. Clin. Invest. 113 (2004) 1218-1224
31. Lohse A.W., et al. Control of experimental autoimmune encephalomyelitis by T cells responding to activated T cells. Science 244 (1989) 820-822
32. Teklenburg G., and Albani S. The role of immune tolerance in preventing and treating arthritis. Curr. Rheumatol. Rep. 6 (2004) 434-441
33. Chen G., et al. Vaccination with selected synovial T cells in rheumatoid arthritis. Arthritis Rheum. 56 (2007) 453-463
34. Vandenbark A.A. TCR peptide vaccination in multiple sclerosis: boosting a deficient natural regulatory network that may involve TCR-specific CD4 CD25 Treg cells. Curr. Drug Targets Inflamm. Allergy 4 (2005) 217-229
35. Joosten L.A., et al. Induction of tolerance with intranasal administration of human cartilage gp-39 in DBA/1 mice: amelioration of clinical, histologic, and radiologic signs of type II collagen-induced arthritis. Arthritis Rheum. 43 (2000) 645-655
36. Choy E.H., et al. Control of rheumatoid arthritis by oral tolerance. Arthritis Rheum. 44 (2001) 1993-1997
37. Barnett M.L., et al. A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis. Arthritis Rheum. 39 (1996) 623-628
38. Sieper J., et al. Oral type II collagen treatment in early rheumatoid arthritis: a double-blind, placebo-controlled, randomized trial. Arthritis Rheum. 39 (1996) 41-51
39. Kalden J.R., and Sieper J. Oral collagen in the treatment of rheumatoid arthritis [editorial]. Arthritis Rheum. 41 (1998) 191-194
40. Cobb B.A., and Kasper D.L. Coming of age: carbohydrates and immunity. Eur. J. Immunol. 35 (2005) 352-356
41. Yamada H., et al. A transient post-translationally modified form of cartilage type II collagen is ignored by self-reactive T cells. J. Immunol. 173 (2004) 4729-4735
42. Dzhambazov B., et al. The major T cell epitope on type II collagen is glycosylated in normal cartilage but modified by arthrats and humans. Eur. J. Immunol. 35 (2005) 357-366
43. Cope A.P., and Sonderstrup G. Evaluating candidate autoantigens in rheumatoid arthritis. Springer Semin. Immunopathol. 20 (1998) 23-39
44. Corrigall V.M., et al. The human endoplasmic reticulum molecular chaperone BiP is an autoantigen for rheumatoid arthritis and prevents the induction of experimental arthritis. J. Immunol. 166 (2001) 1492-1498
45. Prakken B., et al. Heat shock proteins in juvenile idiopathic arthritis: keys for understanding remitting arthritis and candidate antigens for immune therapy. Curr. Rheumatol. Rep. 4 (2002) 466-473
46. Quintana F.J., et al. Inhibition of adjuvant-induced arthritis by DNA vaccination with the 70-kd or the 90-kd human heat-shock protein: immune cross-regulation with the 60-kd heat-shock protein. Arthritis Rheum. 50 (2004) 3712-3720
47. Pockley A.G. Heat shock proteins as regulators of the immune response. Lancet 362 (2003) 469-476
48. Van Eden W., et al. Heat-shock proteins induce T-cell regulation of chronic inflammation [review]. Nat. Rev. Immunol. 5 (2005) 318-330
49. Albani S., et al. Positive selection in autoimmunity: abnormal immune responses to a bacterial dnaJ antigenic determinant in patients with early rheumatoid arthritis. Nat. Med. 1 (1995) 448-452
50. Albani S., et al. Immune responses to the Escherichia coli dnaJ heat shock protein in juvenile rheumatoid arthritis and their correlation with disease activity. J. Pediatr. 124 (1994) 561-565
51. Albani S., and Carson D.A. A multistep molecular mimicry hypothesis for the pathogenesis of rheumatoid arthritis. Immunol. Today 17 (1996) 466-470
52. Prakken A.B., et al. Autoreactivity to human heat-shock protein 60 predicts disease remission in oligoarticular juvenile rheumatoid arthritis. Arthritis Rheum. 39 (1996) 1826-1832
53. De Graeff-Meeder E.R., et al. Juvenile chronic arthritis: T cell reactivit y to human HSP60 in patients with a favourable course of arthritis. J. Clin. Invest. 95 (1995) 934-940
54. Cohen I.R., and Young D.B. Autoimmunity, microbial immunity and the immunological homunculus. Immunol. Today 12 (1991) 105-110
55. Miller, SD, and Karpus, WJ. (2007) Experimental autoimmune encephalomyelitis in the mouse. Curr Protoc Immunol. Chapter 15:Unit 15.1
56. Wauben M.H., et al. Disease inhibition by major histocompatibility complex binding peptide analogues of disease-associated epitopes: more than blocking alone. J. Exp. Med. 176 (1992) 667-677
57. Broere F., et al. Oral or nasal antigen induces regulatory T cells that suppress arthritis and proliferation of arthritogenic T cells in joint draining lymph nodes. J. Immunol. 181 (2008) 899-906
58. Ochsenkühn T., et al. Arthritis after Mycobacterium bovis immunotherapy for bladder cancer. Ann. Intern. Med. 112 (1990) 882
59. Van Eden W., and Waksman B.H. Immune regulation in adjuvant-induced arthritis: possible implications for innovative therapeutic strategies in arthritis. Arthritis Rheum. 48 (2003) 1788-1796
60. La Cava A., et al. Genetic bias in immune responses to a cassette shared by different microorganisms in patients wit rheumatoid arthritis. J. Clin. Invest. 100 (1997) 658-663
61. Prakken B.J., et al. Epitope-specific immunotherapy induces immune deviation of pro-inflammatory T cells in Rheumatoid Arthritis. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 4228-4233
62. van den Broek, et al. Susceptibility to epitope specific immunothrapy of rheumatoid arthritis relies on the expression of co-stimulatory molecules associated with T cell anergy and tolerance. Am. Coll. Rheum. Abstracts 1848 (2008) 50
63. Kamphuis S., et al. Tolerogenic immune responses to novel T cell epitopes from heat-shock protein 60 in juvenile idiopathic arthritis. Lancet 366 (2005) 50-56